Zumenon

Zumenon is a hormone replacement therapy (HRT) tablet containing estradiol, a naturally occurring oestrogen, available in two strengths: 1mg and 2mg. It is used for the relief of menopausal symptoms in women and belongs to the category of unopposed oestrogen therapy, meaning it contains oestrogen without a progestogen component.

Menopause and Oestrogen Deficiency

The menopause occurs when the ovaries cease producing oestrogen, typically between the ages of 45 and 55. The resulting oestrogen deficiency causes a range of symptoms that can significantly affect quality of life: hot flushes, night sweats, vaginal dryness, urinary symptoms, sleep disturbance, mood changes, and cognitive difficulties. In the longer term, oestrogen deficiency accelerates bone mineral loss, increasing the risk of osteoporosis and fragility fractures.

How Zumenon Works

Zumenon contains estradiol, the biologically active form of oestrogen that circulates in pre-menopausal women. When taken as a tablet, estradiol is absorbed from the gastrointestinal tract and enters the systemic circulation, replenishing oestrogen levels and alleviating the symptoms that arise from deficiency. Unlike some older HRT preparations that used conjugated equine oestrogens, Zumenon uses synthetic estradiol that is chemically identical to endogenous human oestradiol.

Unopposed Oestrogen and Endometrial Safety

An important clinical consideration with Zumenon is that it is an unopposed oestrogen preparation. Oestrogen stimulates the growth of the endometrium (the lining of the uterus). In women who have a uterus, unopposed oestrogen taken without a progestogen dramatically increases the risk of endometrial hyperplasia and endometrial cancer. For this reason, Zumenon is only appropriate as sole HRT for women who have had a hysterectomy. Women with an intact uterus who require HRT must take a progestogen alongside Zumenon as part of a combined HRT regimen.

Zumenon is taken orally, one tablet daily on a continuous basis, the same dose every day without breaks. Unlike cyclical or sequential HRT regimens that involve alternating oestrogen and progestogen, Zumenon as an unopposed oestrogen is taken continuously.

Who Should Take Zumenon

Zumenon 1mg or 2mg may be prescribed as sole therapy to women who have had a hysterectomy. For women with a uterus, a progestogen-containing preparation must be added to protect the endometrium. This can be done by prescribing a separate progestogen tablet or by using a combined HRT product. Your prescriber will advise on the most suitable combined regimen.

Dose and Duration

Treatment is usually initiated at the lower 1mg dose to assess tolerability, with titration to 2mg if symptoms are inadequately controlled. Doses should be taken at the same time each day. HRT should be reviewed at least annually by your prescriber, who will assess ongoing benefit, any new risk factors, and whether continuation is appropriate. The lowest effective dose for the shortest duration consistent with treatment objectives is the recommended approach.

Zumenon is available in 1mg and 2mg estradiol tablets. The usual starting dose is 1mg once daily. The dose may be increased to 2mg once daily if symptomatic relief is insufficient. In women with a uterus, a progestogen must be added (e.g. norethisterone 1mg for 12 days per cycle in sequential regimens, or a low-dose progestogen daily in continuous-combined regimens). Zumenon is not appropriate as monotherapy in women with an intact uterus. No dose adjustment is required in mild to moderate renal impairment. Zumenon is not recommended in women with severe hepatic impairment, acute or chronic liver disease, or a history of hormone-sensitive tumours.

Common Side Effects

• Breast tenderness or enlargement
• Nausea
• Headache
• Fluid retention or bloating
• Vaginal bleeding or spotting (particularly in the first months of use)
• Mood changes or irritability
• Mild skin reactions

Serious Side Effects

• Venous thromboembolism: swollen, painful leg, chest pain, or breathlessness, seek emergency care immediately
• Endometrial hyperplasia or cancer: risk in women with intact uterus taking unopposed oestrogen without progestogen
• Breast cancer: long-term use of HRT is associated with a modestly increased risk; annual breast awareness and NHS breast screening participation is recommended
• Stroke or TIA: risk is slightly elevated with oral HRT, particularly in women with pre-existing cardiovascular risk factors

Zumenon must not be used as sole HRT in women who have not had a hysterectomy. Unopposed oestrogen stimulates endometrial proliferation and substantially increases the risk of endometrial cancer in women with an intact uterus. A progestogen must be prescribed alongside Zumenon in these women. Any unscheduled vaginal bleeding during HRT should be investigated promptly, as it may indicate endometrial pathology.

Breast Cancer Risk

All HRT preparations are associated with a modestly increased risk of breast cancer that increases with duration of use. Oral oestrogen-only HRT (as in Zumenon) in women who have had a hysterectomy carries a lower breast cancer risk than combined HRT. Women should be encouraged to participate in the NHS breast screening programme and perform regular breast self-examination. Any new breast lump or unexplained breast change should be reported immediately.

Thromboembolism and Cardiovascular Risk

Oral HRT formulations are associated with a slightly elevated risk of venous thromboembolism compared to non-use. Women with personal or family history of DVT, pulmonary embolism, thrombophilia, or significant obesity should discuss these risks with their prescriber, as a transdermal oestrogen formulation may carry a lower thrombotic risk.

• Known, suspected, or previous oestrogen-dependent malignancy (e.g. breast cancer, endometrial cancer)
• Undiagnosed vaginal bleeding
• Active or past venous thromboembolism (DVT or PE)
• Active or recent arterial thromboembolic event (MI, angina, TIA, stroke)
• Severe hepatic impairment or active liver disease
• Porphyria
• Known thrombophilic disorders (e.g. protein C or S deficiency, antiphospholipid syndrome)
• Pregnancy or breastfeeding
• Use without progestogen in women with intact uterus
• Hypersensitivity to estradiol or any excipient